1
My Patient Isn’t Responding to
PPIs... Now What?
Crescent City GI, Endoscopy & Liver Disease Update
January 12, 2018
Michael S. Smith, MD, MBA
Chief of Gastroenterology and Hepatology
Mount Sinai West & St. Luke’s Hospitals
Associate Professor of Medicine
Icahn School of Medicine at Mount Sinai
Relevant Disclosures
• Endogastric Solutions—Consultant
2
Gastroesophageal Reflux Disease(GERD)
Definition: Symptoms
and/or tissue damage
secondary to reflux of
normal gastric contents
Not all reflux is acid reflux!!!
GERD Pathogenesis• Esophageal causes
– Reduced saliva (e.g. anticholinergic medications)
– Reduced peristalsis (e.g. scleroderma)
– Lack of gravity (e.g. post-operative patient)
– Decreased mucosal resistance due to reduced secretion from
esophageal submucosal glands
• Lower esophageal sphincter dysfunction
– Inappropriate and prolonged LES relaxations
– Presence of a hiatal hernia
– Weak LES (e.g. old age, scleroderma, medications)
• Gastric Causes
– Slow gastric emptying
– Excess acid production
– Duodenogastric (bile) reflux
3
What are the pathogenic factors
in reflux esophagitis?
• Volume of refluxed fluid
• Duration of reflux
• Type of refluxed fluid
• Clearing mechanisms
• Hiatal hernia
Normal Anatomy Prevents GERD
4
Effect of Hiatal Hernia
Acid Reservoir
LES and diaphragm
now separated
Seen by
Gastroenterologists
Seen by
Primary Care Physicians
Do Not Seek
Medical Attention
Chronic Symptoms
and Complications
Frequent
Symptoms
Mild Recurrent
Symptoms
Majority of Patients with GERD
Do Not Seek Medical AttentionGERD ICEBERG
5
Heartburn is a ClassicSymptom of GERD
• Substernal burning and/or
regurgitation
• Postprandial
• Aggravated by change in
position
• Prompt relief by antacids
•ENThoarseness vocal cord granulomas/ulcers
cough laryngeal stenosisglobus laryngeal cancerhalitosis loss of dental enamel
•Pulmonaryasthma apnea
bronchitis atelectasisaspiration pulmonary fibrosis
pneumonia
•Non-Cardiac Chest Pain
Atypical GERD Symptoms
6
Medical Options for GERD Treatment
• Dietary & Lifestyle Modification
• Antacids and Topicals
• Prokinetics
• Baclofen
• H2-receptor antagonists (H2RAs)
• Proton pump inhibitors (PPIs)
Dietary & Lifestyle ModificationsFrom the ACG Guidelines1:
• Weight loss is recommended for GERD patients who are overweight or
have had recent weight gain. (Conditional recommendation, moderate
level of evidence)
• Head of bed elevation and avoidance of meals 2–3 hours before bedtime
should be recommended for patients with nocturnal GERD. (Conditional
recommendation, low level of evidence)
• Routine global elimination of food that can trigger reflux (including
chocolate, caffeine, alcohol, acidic and/or spicy foods) is not
recommended in the treatment of GERD. (Conditional recommendation,
low level of evidence)
• Tobacco and alcohol cessation have not been shown to change either
GERD symptoms or esophageal pH 2-4
1 Katz PO, Gerson LB, Vela MF. Am J Gastroenterol 2013; 108:308 – 328.2 Schindlbeck NE , Heinrich C , Dendorfer A et al. Gastroenterology 1987 ; 92 : 1994 – 7.3 Waring JP , Eastwood TF , Austin JM et al. Am J Gastroenterol 1989 ; 84 : 1076 – 8.4 Kadakia SC , Kikendall JW , Maydonovitch C et al. Am J Gastroenterol 1995 ; 90 : 1785 – 90.
7
Antacids & Topicals• Antacids:
– Examples: calcium carbonate, aluminum hydroxide, magnesium trisilicate
– Do not prevent GERD, only treat its symptoms by neutralizing gastric pH which
decreases the acidity of any refluxate
– Rapid onset of action (<5 minutes) but short duration of efficacy (<1 hour)
• Sucralfate:
– Available in both tablet and suspension form
– Adheres to esophageal wall and protects from peptic injury via unknown
mechanism
– Short duration of action, limited efficacy compared to PPIs
– ACG Guidelines: There is no role for sucralfate in the non-pregnant GERD
patient. (Conditional recommendation, moderate level of evidence)
• Sodium alginate:
– Derived from seaweed
– Forms a viscous gum which floats on the surface of gastric contents, reducing
the postprandial “acid pocket” in the proximal stomach 1
– Studies suggest it may be beneficial, especially with mild post-prandial
symptoms 1
1 Thomas E, Wade A, Crawford G et al. Aliment Pharmacol Ther 2014; 39: 595.
Prokinetics & Other Non-Acid Reducers• Prokinetics
– Examples include metoclopramide and domperidone
– Can increase lower esophageal sphincter pressures, improve peristalsis in
addition to promoting gastric emptying 1
– Metoclopramide CNS-based side effects include depression and tardive
dyskinesia (black box warning from FDA)
– Domperidone does not penetrate the blood-brain barrier but does carry a risk
of ventricular arrhythmia; also requires and IDA from the FDA
• Baclofen
– GABA(b) agonist shown to decrease TLESRs and reflux events 2-4
– Not currently approved by the FDA for treatment of GERD
– Lack of long-term data regarding efficacy in GERD
– Potential side effects of dizziness, somnolence, constipation
• ACG Guidelines:
– Therapy for GERD other than acid suppression, including prokinetic therapy
and/or baclofen, should not be used in GERD patients without diagnostic
evaluation. (Conditional recommendation, moderate level of evidence)
1 Champion MC. Can J Gastroenterol 1997; 11 (Suppl B): 55B – 65B.2 Grossi L , Spezzaferro M , Sacco LF et al. Neurogastroenterol Motil 2008 ; 20: 760 – 6.3 Koek GH , Sifrim D , Lerut T et al. Gut 2003 ; 52 : 1397 – 402.4 Vela MF , Tutuian R , Katz PO et al. Aliment Pharmacol Ther 2003 ; 17 : 243 – 51.
8
H2Receptor Antagonists (H2RAs)• Act on type 2 histamine receptors on the basal side of the parietal
cell
• Faster onset of action than PPIs, but shorter half life
• Dosing for mild GERD generally is PRN or BID
• Studies have shown superiority of PPIs over H2RAs for relief of
heartburn in NERD patients (7 trials with RR of continued
heartburn 0.37 for PPIs, 0.77 for H2RAs, 95% CI 0.60-0.73) 1
• ACG Guidelines:
– H2RA therapy can be used as a maintenance option in patients without erosive
disease if patients experience heartburn relief. (Conditional recommendation,
moderate level of evidence).
– Bedtime H2RA therapy can be added to daytime PPI therapy in selected
patients with objective evidence of night-time reflux if needed, but may be
associated with the development of tachyphylaxis after several weeks of use.
(Conditional recommendation, low level of evidence)
1 van Pinxteren B , Sigterman KE , Bonis P et al. Cochrane Database Syst Rev : CD002095 .
Histamine
Acetylcholine
Gastrin
PGE2
ATPase
Antacids
Proton pump
inhibitors
H+
Therapeutic Modalities to Affect Gastric Acid Secretion
Histamine
Acetylcholine
Gastrin
Anticholinergic agents
H2-receptor antagonists
Gastric receptor antagonists
PGE2
ATPase
Antacids
Proton pump
inhibitors
H+
9
Long-Term Esophagitis Remission100
90
80
70
60
50
40
30
20
10
00 2 4 6 8 10 12
Months
Pe
rce
nt
Pa
tie
nts
in
Re
mis
sio
n
Dent, J, et al. Gut 1994;35:593.
20 mg Omeprazole
every morning
20 mg Omeprazole
weekends
150 mg ranitidine
twice daily
10
The Expanding Family of
Proton Pump Inhibitors
•Omeprazole (Prilosec) 1989
•Lansoprazole (Prevacid) 1995
•Rabeprazole (Aciphex) 1999
•Pantoprazole (Protonix) 2000
•Esomeprazole (Nexium) 2001
•Omeprazole/NaHCo3 (Zegerid) 2004
•Dexlansoprazole (Dexilant) 2009
• Response to PPI trial now has become an accepted
“first test” in suspected GERD
• “Red Flags” where empiric PPI should not be used:
– Age > 50
– Dysphagia
– Odynophagia
– Iron Deficiency Anemia
– Hematochezia
– Failure to respond to prior trial of acid reduction
Empiric PPI Therapy forSuspected GERD
11
• Are they actually taking it?
• Are they taking it correctly? (30-60 min before meals)
• Are they taking the proper dose?
• Are they not responding to this particular PPI?
• Do they have refractory acid reflux?
• Do they have refractory GERD, but not excess acid?
• Are their symptoms not (just) due to GERD?
Why Hasn’t My Patient Improved on PPI?
• Do you have a compliant patient (diet, meds)?
• What exactly are the symptoms the patient has at this time, and have they improved or changed at all with PPI use?
– Typical (reflux, heartburn, regurgitation)
– Atypical
• How likely is it that the patient has GERD, and could there be another etiology for the symptoms (either primary cause or exacerbating factor for GERD)?
Step 1: Take a Great History
12
• Trial the patient on BID PPI for at least 2-3 months before they are deemed a PPI failure, when GERD is suspected
• Atypical symptoms often take longer to resolve than typical symptoms, so make sure the patient knows to complete the whole trial rather than give up in 2 weeks if they don’t feel 100% better
Step 2: Complete a BID PPI Trial(if not already done)
• Make your best clinical guess—how likely is it that this patient really has reflux disease?
– At least partial response to PPI increases this
likelihood
– No change at all to a reasonably dosed BID PPI
decreases the likelihood
• This risk stratification affects the choice of subsequent quantitative reflux testing
Step 3: Risk Stratify the Patient for Having Refractory GERD
13
• High resolution esophageal manometry with impedance
• Quantitative reflux testing
– 48 hour wireless pH-metry
– 24 hour pH-impedance
• Endoscopy
• Barium esophagram
• Gastric emptying scintigraphy
Step 4: Additional Testing to Quantify GERD and Assess for
Other Potential Etiologies
What is Esophageal Manometry?
• Mano = pressure, metry = measure
• Previous measurements taken with
water-perfused catheters
• Current high resolution models use
solid state transducers (36 at 1 cm
intervals)
• Catheters also include 18 impedance
transducers to evaluate for presence of
(conducting) liquids in the esophagus
• Catheter is placed transnasally and
patient is awake during the study
14
What Does Manometry Evaluate?
• Upper esophageal sphincter (resting pressure and post-
deglutition/residual pressure)
• Esophageal contraction
– Presence or absence of contraction (skeletal and smooth muscle)
– Pattern of contraction
– Propagation velocity
– Amplitude of contraction
• Lower esophageal sphincter (resting pressure and post-
deglutition/residual pressure)
Normal Swallow on Manometry
Upper Esophageal
SphincterSkeletal Muscle
ContractionTransition Zone
Smooth Muscle
Contraction
Lower Esophageal
Sphincter
16
The Chicago Classification
• Used to group motility disorders identified on manometry
• Provides a standardized nomenclature for describing
motility disorders of the esophagus
• Now on its third iteration
• Utilizes an algorithm to “read” studies and provide a
diagnosis:
1) Are there abnormalities of the lower esophageal sphincter/
esophago-gastric junction region?
2) Are there abnormalities of esophageal contractility?
3) Are there patterns of abnormal pressurization?
18
Type III Achalasia
EG Junction Outflow Obstruction
• Differential diagnosis:
– Mechanical obstruction
(subtle stricture or ring);
consider barium study
with a barium tablet or
barium-coated solid
object
– Incomplete achalasia
19
Other Major Peristaltic Disorders
Diffuse Esophageal Spasm Jackhammer Esophagus
Absent Peristalsis/Contractility
• 100% failed swallows (DCI < 100 mmHg-cm-s)
• Normal IRP (< 15 mmHg)
• Includes scleroderma-like esophagus
20
Treating Major Peristaltic Disorders
Overly Vigorous Peristalsis:
• Pharmacotherapy:
– PPI is preferred first option (is this effect of GERD?)
– Pain modulators (Tricyclics, SSRIs, SNRIs, Trazodone)
– Smooth muscle relaxants (CCBs, Nitrates, PDE-5 inhibitors)
• Botulinum toxin injection of distal esophagus
• Surgical (Heller) myotomy
• POEM (Per Oral Endoscopic Myotomy)
Absent Peristalsis:
• Management of GERD (PPI, Partial Fundoplication)
“Minor” Disorders of Peristalsis
• Ineffective Esophageal Motility: 50%+ ineffective swallows
(either failed or DCI < 450 mmHg-s-cm)
• Fragmented Peristalsis: 50%+ fragmented, DCI>450
21
Treating Minor Peristaltic Disorders
• Mainstay of treatment is controlling GERD that is
exacerbated by these disorders
– Acid reduction therapy
– Partial fundoplication
• Could this be opioid-induced?
• Some believe in potential role for prokinetic therapy
– Tegaserod
– Bethanecol
– Pyridostigmine
– Buspirone
– Metoclopramide
– Erythromycin
Side effects and
potential for
tachyphylaxis
limit utility of
these agents
Transient
Lower
Esophageal
Sphincter
Relaxation
22
• Low likelihood of GERD: 48 hour wireless pH-metry OFF
acid reducers
– Answer the key question: does this patient even have GERD in
the first place?
– Very unlikely patient has excess non-acid reflux if there is no
excess acid reflux
• Higher likelihood of GERD: 24 hour pH-impedance testing
ON BID PPI
– Quantifies reflux
Quantitative Reflux Testing Options
Wireless pH-Metry vs. pH-ImpedanceLikely GERD:
24 hourpH/impedance on BID PPI
Unlikely GERD:48 hour wirelesspH-Metry off PPI
23
What Data Does pH Testing Provide?
48 hour wireless pH-Metry:
• # of acid reflux events
• % time pH < 4 (upright, supine, total)
• DeMeester score (predict response
to antireflux surgery)
• Correlation of symptoms with acid
reflux events
• Ability to expand to 96 hours of data
24 hour pH/impedance:
• # of acid reflux events
• # of weakly acidic/non-acidic events
• % time pH < 4 (upright, supine, total)
• Degree of esophageal stasis
• DeMeester score (predict response to
antireflux surgery)
• # of proximal reflux events
• Correlation of symptoms with acid
reflux events
• Correlation of symptoms with weakly
acidic and non-acidic reflux events
Evaluating GERD: Endoscopy
• Strengths- Esophagitis,
Barrett’s epithelium- Hiatal hernia,
strictures- Biopsy
• Limitations- Operator dependent- Cost
Endoscopy with biopsy is the best diagnostic
study for evaluating mucosal injury.
24
Evaluating GERD: Radiology
BariumEsophagram
• 4 HOUR test to assess rate of gastric emptying
• Generally done with egg and toast meal (set portion), but
also can be done with a liquid version
• Key measurements: percent of meal retained at 2 hours
(normal <=60%) and at 4 hours (normal <=10%)
• Not an uncommon cause of (refractory) reflux, which
could be a primary symptom along with nausea, vomiting
and early satiety
Gastric Emptying Scintigraphy
25
Relative Value of DiagnosticTests in GERD
Diagnostic tests should be performed in individualGERD patients to answer specific questions
Ambulatory
Barium pH
Swallow Endoscopy Monitoring Manometry
Dysphagia +++ ++ - +
Mucosal Injury + +++ - -
Quantitate reflux + - +++ -
Atypical symptoms + + +++ -
• Esophageal motility disorder
• Eosinophilic Esophagitis
• Peptic stricture
• Paraesophageal hernia causing outflow obstruction
• Gastroparesis
• Esophageal visceral hypersensitivity
• Functional dyspepsia
Step 5: Find your Diagnosis/es
TCAs, SSRIs, SNRIs,
Neuromodulators
26
Tailor to the patient’s specific symptoms and their timing, if
testing confirms excess acid exposure despite BID PPI
• Double-dose H2-Receptor antagonist at bedtime
• Sodium alginate with meals
• Sucralfate to heal erosive esophagitis
Step 6: Augment Medical Management of Acid Reflux?
Surgical Alternatives
for Managing Refractory GERD
27
Indications for Surgery in 2018
• Healthy GERD patient controlled on PPIs
– Cost of continuing lifelong PPI treatment
– Compliance with lifelong medication
– Ongoing side effects with current use
– Fear of side-effects of long term use
• Atypical GERD symptoms relieved on PPIs
• Esophagitis refractory to medical therapy
• Volume regurgitation and aspiration symptoms not
controlled on PPIs
– Large hiatal hernia
• Persistent symptoms documented to be caused by
refractory GERD (pH/impedance testing)
Nissen Fundoplication
• 360 degree wrap of fundus around the
esophago-gastric junction to bolster the
lower esophageal sphincter
• Mostly performed laparoscopically
• 10 year follow-up of VA study 1
– 62% of Nissens using medical therapy, vs. 92%
of non-surgical patients
• 12 year follow-up in separate study 2
– 53% of Nissens in remission, vs. 45% of PPIs
• Most common side effects:
– Gas-bloat (up to 15-20% of patients)
– Dysphagia (generally transient but not always)1 Spechler SJ , Lee E , Ahnen D et al. JAMA 2001 ; 285 : 2331 – 8 .2 Lundell L, Miettinen P, Myrvold HE et al. Clin Gastroenterol Hepatol 2009 ; 7: 1292 – 8 .
28
Nissen Fundoplication versus PPI
Lundell et al. Am J Coll Surg 2001
Other Surgical Options
• Toupet Fundoplication:
– 270-300 degree wrap of fundus around the
esophago-gastric junction
– Thought to generate less dysphagia
– Preferred approach for refractory GERD in the
setting of known esophageal dysmotility
• Roux-en-Y Gastric Bypass:
– Creates physical separation between oxyntic
mucosa of the stomach and the esophagus
– Facilitates weight loss along with decreased
acid exposure to the distal esophagus
– May be the preferred option for long-term
GERD management in obese patients
29
Magnetic Sphincter Augmentation
• Ring of titanium beads encasing magnetic cores
placed surgically at the level of the lower
esophageal sphincter
• Size of ring (number of beads) selected based on
esophageal measurement at time of placement
• Magnetic forces augment LES pressure to
approximately 15 mmHg
• Passage of a bolus through the esophago-gastric
junction allows for dynamic opening of the ring,
as pressure generated by the bolus overcomes that
of the beads
• Goal of this system is to allow for pressure-
induced opening of the LES, which is not possible
after suturing during a fundoplication (belching
and vomiting possible, less dysphagia, etc.)
• Data now available on 85 patients at 5 years
30
Results at 5 Years
Ganz RA, Edmundowicz SA, Taiganides PA. Clin Gastroenterol Hepatol. 2016 ; 14(5) : 671 – 7.
ACG Guidelines• Surgical therapy is a treatment option for long-term
therapy in GERD patients. (Strong recommendation,
high level of evidence)
• Surgical therapy is as effective as medical therapy for
carefully selected patients with chronic GERD when
performed by an experienced surgeon. (Strong
recommendation, high level of evidence)
• Surgical therapy is generally not recommended in
patients who do not respond to PPI therapy. (Strong
recommendation, high level of evidence)
31
ACG Guidelines II• Preoperative ambulatory pH monitoring is mandatory
in patients without evidence of erosive esophagitis. All
patients should undergo preoperative manometry to
rule out achalasia or scleroderma-like esophagus.
(Strong recommendation, moderate level of evidence)
• Obese patients contemplating surgical therapy for
GERD should be considered for bariatric surgery.
Gastric bypass would be the preferred operation in
these patients (Conditional recommendation, moderate
level of evidence)
Electrical Stimulation Therapy of LES
• Implantation performed with laparoscopy
• 2 small leads placed on LES
• Neurostimulator connected to leads sends mild
electrical signals throughout the day (not
generally sensed by patients) to improve LES
function
• 2 year data of multi-center trial1
– 21 patients with GERD partially responsive to GERD
and hiatal hernia 3 cm long or less made interim analysis
– Median GERD-HRQL scores dropped from 9 to 0
(comparing current to pre-EST scores on and off PPI)
– 16/21 patients totally off PPI
– 2/21 patients using PPI daily
– Median 24 hour distal acid exposure was 10% at baseline
and 4% (per protocol, p < 0.001)
– No serious adverse events reported
1Rodriguez et al. Surgery. 2015; 157(3): 566-7.
32
Endosurgical Options
for Managing Refractory GERD
Radiofrequency Energy
• Ablation performed at 6 levels in the
region of the esophagogastric junction
• Outpatient endoscopic procedure
• Does not preclude use of other anti-
reflux measures in the future
33
RF: Potential Mechanism of Action
• Increases gastric yield pressure in pig model vs. control 1
• Reduces transient LES relaxations (TLESRs) when applied
to the gastric cardia in dogs 2
• Randomized control study of 22 patients 3:
– RFA decreased GEJ compliance compared to sham patients
– Use of sildenafil (smooth muscle relaxant) 3 months after RFA
restored normal compliance, suggesting fibrosis is not the driving
force behind decreased compliance
1 Utley D et al. Gastrointest Endosc. 2000 ; 52 : 81 – 86. 2 Kim M et al. Gastrointest Endosc. 2003 ; 57 : 17 – 22.3 Arts J et al. Am J Gastroenterol. 2012 ; 107 : 222 – 230.
RF: Meta-analysis of 1,441 Patients
1 Perry K et al. Surg Laparosc Endosc Percutan Tech. 2012 ; 22(4) : 283 – 288.
34
RF: Durability of Response
• 99 study patients with refractory GERD followed for 10
years
• PPI needs: 64% no longer required the same dose of PPI as pre-RF, and
41% remained off PPIs completely
• Normalization of GERD-HRQL scores (primary endpoint) in 70% of
patients
• Response rate in patients with variant anatomy and prior anti-reflux
surgery was the same as those with standard anatomy
1 Noar M, Squires P, Noar E et al. Surg Endosc. 2014. 28(8) : 2323 – 33.
RF: Endorsed by SAGES
http://www.sages.org/publications/guidelines/endoluminal-treatments-for-gastroesophageal-reflux-disease-gerd/
35
Transoral Incisionless
Fundoplication (TIF)
• H-shaped fasteners applied for full-thickness plication to
recreate the gastroesophageal flap valve
• Final result is a 2-3 cm long valve of approximately 270
degrees
• Requires hiatal hernia of no more than 2 cm pre-TIF
Gastroenterology 2015
36
TIF: Improvement Through 12 Months
Trad KS, Simoni G, Barnes WE et al. BMC Gastroenterol. 2014 ; 14: 174.
Trad KS, Barnes WE, Simoni G. et al. Surg Innov. 2015 ; 22(1) : 26 – 40.
52%
33%
54%
45%
5%
67%62%
77%
0%
71%
90%
82%
38%
85%90%
100%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
PPI Group (6mo) PPI Crossover (6mo after TIF) TIF Group (6mo) TIF Group (12mo)
Esophageal Acid Exposure (EAE) Complete Symptom Elimination Complete PPI Cessation Esophagitis Healed
• Randomized control trial of high-dose PPIs vs. TIF
• PPI patients crossed over to have TIF after 6 months
• 39 TIF and 21 crossover patients studied
• Significant improvement in symptom elimination (p < 0.001)
and healing of esophagitis (p < 0.018)
TIF: Durability Through 24 Months
Bell et al, Am Surg. 2014 ; 80(11) : 1093 - 1105.
• Prospective U.S. Registry to assess 2 year outcomes
• Primary endpoint: symtpom assessment
• 108 patients completed study
0
5
10
15
20
25
30
35
40
Screening 6-month 12-month 24-month
GERD - HRQL Regurgition RSI GERSS
To
tal S
co
res
37
Ultrasonic Surgical Endostapler
• Disposable endoscopic system contains ultrasound sensor to
facilitate firing of 3 rounds of 4.8 mm titanium staples
• End result is a 150-180 degree anterior fundoplication
Pre-Procedure Post-Procedure
3rd Stapling
1
2
3
Still images from Dr. Ali Lankarani via https://youtu.be/fsuFKk5MlLc
Ultrasonic Endostapler: Key Data
1 Zacherl J et al Surg Endoscopy. 2015 ; 29(1) : 220 – 9.2 Kim HJ et al. Surg Endoscopy. 2016 ; 30(8) : 3402 – 8.
• 66 patients in multi-center trial (6 month data) 1
– 65% of patients off PPI
– 85% either off PPI or with 50%+ reduction in PPI use
• 34 patients in multi-center trial followed at least 4 years 2
– 69% remain off PPI at conclusion of study period
38
Conclusions• PPIs remain the most potent acid-reducing agent in our
medical arsenal for treating GERD; switching to another
medication is unlikely to improve control of reflux (acid or non-
acid)
• If a patient continues to be symptomatic despite PPI therapy,
ensure they are taking their medication correctly and at the
proper dose, then confirm refractory GERD with 24 hour
pH/impedance testing on medication
• Prior to any mechanical intervention for reflux, check
esophageal function with manometry to exclude dysmotility
• Surgical intervention remains the best option for improving
the mechanical barrier to gastroesophageal reflux, as new
options show promise as alternatives to Nissen fundoplication
• Endoscopic techniques to bolster the anti-reflux barrier show
promise, with sample size and durability data forthcoming
Thank YouThank YouThank YouThank You!!!!
[email protected]@[email protected]@mountsinai.org